Glinidas. Revisión de su uso terapéutico en la diabetes mellitus tipo 2

Pérez, O. Moreno; Alfonso, Antonio Picó; Marrahí, Paula Revert; Fuster, Sandra Martínez

doi:10.1016/s1575-0922(08)76260-0

Cited by 1 publication

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With respect to the products 2 , 3 , 7 , 8 , 9 , and 10 , they showed activity in terms of the hyperglycemic values. This activity was considered antihyperglycemic activity because when they were evaluated in NM mice, they did not generate hypoglycemia, and in SID2 they reduced the hyperglycemic levels [7,8,18]: this activity was similar to that observed with acarbose. The compounds 2 , 3 , 7 , 8 , 9 , and 10 were selected to continue the study.…”

Section: Discussionmentioning

confidence: 98%

“…The World Health Organization (WHO) estimates that worldwide, from 1995 to the current day, the number of people living with DM has tripled, with an estimated value of more than 425 million people (8.8%), with a range age between 20 and 79 years [4,5]. There are several treatments for this disease, including sulfonylureas, meglitinides, biguanides, thiazolidinediones, glucagon-like peptide-1 (GLP-1) analogs, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium–glucose cotransporter (SGLT) inhibitors [6,7,8,9]. …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Structure–Activity Relationship Study of Acyclic Terpenes in Blood Glucose Levels: Potential α-Glucosidase and Sodium Glucose Cotransporter (SGLT-1) Inhibitors

2019

View full text Add to dashboard Cite

Twelve terpenoids were evaluated in the treatment of type 2 diabetes mellitus: seven monoterpenes (geranyl acetate (1), geranic acid (2), citral (3), geraniol (4), methyl geranate (5), nerol (6), and citronellic acid (7)), three sesquiterpenes (farnesal (8), farnesol (9), and farnesyl acetate (10)), one diterpene (geranylgeraniol (11)), and one triterpene (squalene (12)) were selected to carry out a study on normoglycemic and streptozotocin-induced diabetic mice. Among these, 2, 3, 7, 8, 9, and 10 showed antihyperglycemic activity in streptozotocin-induced diabetic mice. They were then selected for evaluation in oral sucrose and lactose tolerance tests (OSTT and OLTT) as well as in an oral glucose tolerance test (OGTT). In the OSTT and OLTT, compounds 3, 7, 8, 9, and 10 showed a reduction in postprandial glucose peaks 2 h after a sucrose or lactose load (comparable to acarbose). In the case of the OGTT, 2, 7, 8, 9, and 10 showed a reduction in postprandial glucose peaks 2 h after a glucose load (comparable to canagliflozin). Our results suggest that the control of postprandial hyperglycemia may be mediated by the inhibition of disaccharide digestion, such as sucrose and lactose, and the regulation of the absorption of glucose. The first case could be associated with an ∝-glucosidase inhibitory effect and the second with an inhibition of the sodium–glucose type 1 (SGLT-1) cotransporter. Finally, five acyclic terpenes may be candidates for the development and search for new α-glucosidase and SGLT-1 cotransporter inhibitors.

show abstract

Section: Discussionmentioning

confidence: 98%